Key statistics
As of last trade Heron Therapeutics Inc (AXD2:FRA) traded at 2.04, -41.01% below its 52-week high of 3.46, set on Jun 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.83 |
---|---|
High | 2.04 |
Low | 1.83 |
Bid | 1.73 |
Offer | 1.86 |
Previous close | 1.79 |
Average volume | 2.54k |
---|---|
Shares outstanding | 151.67m |
Free float | 150.62m |
P/E (TTM) | -- |
Market cap | 321.54m USD |
EPS (TTM) | -0.3249 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 10:45 BST.
More ▼
Press releases
- Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
- Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
- Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
- Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024
- Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
More ▼